Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.43 |
| ▸ | WNT3A | P56704 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4300704 | 0.90 | SMN1; SMN2 (0.71) | SMN1; SMN2KDM4ESTAT3HIF1AALDH1A1 | |
| SCHEMBL23914670 | 0.85 | SMN1; SMN2 (0.48) | SMN1; SMN2KDM4ESTAT3HIF1ACYP1A2 | |
| SCHEMBL23966522 | 0.83 | ALDH1A1 (0.56) | SMN1; SMN2KDM4ECYP1A2ALDH1A1MAPT | |
| SCHEMBL23908935 | 0.82 | LMNA (0.62) | SMN1; SMN2KDM4ESTAT3HIF1ACYP1A2 | |
| SCHEMBL21591507 | 0.81 | CYP1A2 (0.58) | SMN1; SMN2KDM4ESTAT3HIF1ACYP1A2 | |
| SCHEMBL23914767 | 0.81 | MAP2K4 (0.51) | SMN1; SMN2CYP1A2MAPT | |
| SCHEMBL23914681 | 0.80 | SMN1; SMN2 (0.51) | SMN1; SMN2KDM4ESTAT3HIF1AALDH1A1 | |
| SCHEMBL9328808 | 0.79 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EALDH1A1MAPTGAA | |
| SCHEMBL3035725 | 0.78 | KDM4E (0.54) | SMN1; SMN2KDM4ESTAT3HIF1AALDH1A1 | |
| SCHEMBL29589005 | 0.76 | KDM4E (0.51) | SMN1; SMN2KDM4ESTAT3HIF1ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| CN-110869359-A | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | 加拉帕戈斯股份有限公司 | 2020-03-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | SMN1; SMN2 2920/4885KDM4E 3835/4885STAT3 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.